In addition, in preclinical breast cancer models, GLUT1 inhibitors have shown synergistic effects with current cancer therapies, including radiation treatment, cisplatin, paclitaxel, and adriamycin [129,130,131]. Here, SLC2A1 is linked to breast cancer.